Abstract
J‐107088 (6‐N‐(1‐hydroxymethyl‐2‐hydroxy)ethylamino‐12,13‐dihydro‐2,10‐dihydroxy‐13‐(β‐D‐glu‐copyranosyl)‐5H‐indolo[2,3‐a]‐pyrrolo [3,4‐c]carbazole‐5,7(6H)‐dione) is a derivative of NB‐506, an indolocarbazole compound previously reported as an anti‐tumor agent targeting topoisomerase L The optimal administration schedule of J‐107088 was found to be intermittent injections. The GID75 (75% growth inhibiting total dose) values of J‐107088 against LX‐1 lung cancer and PC‐3 prostate cancer when given by intermittent injection (twice a week for 2 consecutive weeks) were 200 and 15 mg/m2, respectively, whereas the 10% lethal dose (LD10) values of J‐107088 against LX‐1‐ and PC‐3‐bearing mice were 578 and 1200 mg/m2. The ratio of LD10/GID75 indicates the therapeutic window of an anti‐tumor agent. Although the ratios of doxorubicin, paclitaxel and cisplatin against PC‐3 were <0.3, <0.5 and <0.2, J‐107showed the widest therapeutic window among the anti‐tumor drugs tested. J‐107088 was also effective on cells that had acquired resistance related to P‐glycoprotein. Furthermore, J‐107088 was found to be highly effective in inhibiting proliferation of micro‐metastases of tumors to the liver in mice. Therefore, J‐107088 is considered to be a promising candidate as an anti‐tumor drug for treatment of solid tumors in humans.
Keywords: Anti‐tumor, J‐107088, Indolocarbazole, Toxicity, Metastasis
Full Text
The Full Text of this article is available as a PDF (126.7 KB).
REFERENCES
- 1. ) Yoshinari , T. , Matsumoto , M. , Arakawa , H. , Okada , H. , Noguchi , K. , Suda , H. , Okura , A. and Nishimura , S. , Novel antitumor indolocarbazole compound 6‐N‐formylamino‐12, 13‐dihydro‐1,11 ‐dihydroxy‐13‐(β‐D‐glucopyranosyl)‐5H‐indolo‐[2,3‐a]pyrrolo[3,4‐c]carbazole‐5,7(6H)‐dione (NB‐506): induction of topoisomerase I‐mediated DNA cleavage and mechanisms of cell line‐selective cytotoxicity . Cancer Res. , 55 , 1310 – 1315 ( 1995. ). [PubMed] [Google Scholar]
- 2. ) Arakawa , H. , Iguchi , T. , Morita , M. , Yoshinari , T. , Kojiri , K. , Suda , H. , Okura , A. and Nishimura , S.Novel indolocarbazole compound 6‐N‐formylamino‐2,13‐dihydro‐1,11‐dihydroxy‐13‐(β‐D‐glucopyranosyl)‐5H‐indolo[2,3‐a]pyrrole‐[3,4‐c]carbazole‐5,7(6H)‐dione (NB‐506): its potent antitumor activity in mice . Cancer Res. , 55 , 1316 – 1320 ( 1995. ). [PubMed] [Google Scholar]
- 3. ) Yoshinari , T. , Ohkubo , M. , Fukasawa , K. , Egashira , S. , Hara , Y. , Matsumoto , M. , Nakai , K. , Arakawa , H. , Morishima , H. and Nishimura , S.Mode of action of a new indolocarbazole anticancer agent, J‐107088, targeting topoisomerase I . Cancer Res. , 59 , 4271 – 4275 ( 1999. ). [PubMed] [Google Scholar]
- 4. ) Arakawa , H. , Matsumoto , H. , Morita , M. , Sasaki , M. , Taguchi , K. , Okura , A. and Nishimura , S.Antimetastatic effect of a novel indolocarbazole (NB‐506) on IMC‐HM murine tumor cells metastasized to the liver . Jpn. J. Cancer Res. , 87 , 518 – 523 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. ) Ohkubo , M. , Nishimura , T. , Jona , H. , Honma , T. and Morishima , H.Practical synthesis of indolopyrrolocarbazoles . Tetrahedron , 52 , 8099 – 8112 ( 1996. ). [Google Scholar]
- 6. ) Dexter , D. L. , Hesson , D. P. , Ardecky , R. J. , Rao , G. V. , Tippett , D. L. , Dusak , B. A. , Paull , K. D. , Plowman , J. , DeLarco , B. M. , Narayanan , V. L. and Forbes , M.Activity of a novel 4‐quinolinecarboxylic acid, NSC 3688390 [6‐flu‐oro‐2‐(2′‐fluoro‐1,1′‐biphenyl‐4‐yl)‐3‐methyl‐4‐quinolinecar‐boxylic acid sodium salt], against experimental tumors . Cancer Res. , 45 , 5563 – 5568 ( 1985. ). [PubMed] [Google Scholar]
- 7. ) Freireich , E. J. , Gehan , E. A. , Rall , D. P. , Schmidt , L. H. and Skipper , H. E.Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man . Cancer Chemother. Rep. , 50 , 219 – 244 ( 1966. ). [PubMed] [Google Scholar]
- 8. ) Kojiri , K. , Kondo , H. , Yoshinari , T. , Arakawa , H. , Nakajima , S. , Satoh , F. , Kawamura , K. , Okura , A. , Suda , H. and Okanishi , M.A new antitumor substance, BE‐13793C, produced by a streptomycete. Taxonomy, fermentation, isolation, structure determination and biological activity . J. Antibiot. (Tokyo) , 44 , 723 – 728 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Arakawa , H. , Iguchi , T. , Yoshinari , T. , Kojiri , K. , Suda , H. and Okura , A.ED‐110, a novel indolocarbazole, prevents the growth of experimental tumors in mice . Jpn. J. Cancer Res. , 84 , 574 – 581 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. ) Yoshinari , T. , Yamada , A. , Uemura , D. , Nomura , K. , Arakawa , H. , Kojiri , K. , Yoshida , E. , Suda , H. and Okura , A.Induction of topoisomerase I‐mediated DNA cleavage by a new indolocarbazole, ED‐110 . Cancer Res. , 53 , 490 – 494 ( 1993. ). [PubMed] [Google Scholar]
- 11. ) Ohkubo , M. , Kojiri , K. , Kondo , H. , Tanaka , S. , Kawamoto , H. , Nishimura , T. , Nishimura , I. , Yoshinari , T. , Arakawa , H. , Suda , H. , Morishima , H. and Nishimura , S.Synthesis and biological activities of topoisomerase I inhibitors, 6‐N‐amino analogues of NB‐506 . Bioorg. Med. Chem. Lett. , 9 , 1219 – 1224 ( 1999. ). [DOI] [PubMed] [Google Scholar]
- 12. ) Bailly , C. , Qu , X. , Chaires , J. B. , Colson , P. , Houssier , C. , Ohkubo , M. , Nishimura , S. and Yoshinari , T.Substitution at the F‐ring N‐imide of the indolocarbazole antitumor drug NB‐506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities . J. Med. Chem. , 42 , 2927 – 2935 ( 1999. ). [DOI] [PubMed] [Google Scholar]